Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 12/20 | 0.51 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765661 | 0.85 | NAAA (0.58) | NAAAGPBAR1ASAH1 | |
| SCHEMBL3930648 | 0.85 | NAAA (0.58) | NAAAGPBAR1ASAH1 | |
| SCHEMBL5180974 | 0.85 | NAAA (0.58) | NAAAGPBAR1ASAH1 | |
| SCHEMBL21733296 | 0.74 | EPHX1 (0.61) | NAAAMEN1KMT2A | |
| SCHEMBL17557047 | 0.73 | NAAA (0.64) | NAAAASAH1 | |
| SCHEMBL5200673 | 0.73 | CRBN (0.60) | NAAAASAH1 | |
| SCHEMBL632914 | 0.73 | CRBN (0.60) | NAAAASAH1 | |
| SCHEMBL3544056 | 0.73 | CRBN (0.60) | NAAAASAH1 | |
| SCHEMBL14543133 | 0.72 | MEN1 (0.54) | MMP2MMP9MMP12MEN1KMT2A | |
| SCHEMBL17556869 | 0.72 | NAAA (0.77) | NAAAASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, NPC1L1 | NAAA 3657/4885GPBAR1 691/4885MMP2 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.